Urologic Neoplasms Clinical Trial
Official title:
Genetic Analysis of Inherited Urologic Malignant Disorders: Collection of Samples
Investigation of the causes of genetic defects relating to hereditary urologic malignancies
will be undertaken. These rare disorders result from inherited or newly arising mutations in
genes involved in the development and function of different organ systems. As specific
disease syndromes are recognized and the responsible genes identified, mutations in
individual families can be identified. Correlation of mutation sites with clinical
information will help determine how specific gene segments encode important functional
protein domains.
Families with urologic malignant disorders of known or suspected genetic basis will be
enrolled. Genetic linkage studies will include all available family members, while gene
sequence analysis will be performed on affected individuals. Unaffected family members or
unrelated normal individuals will serve as controls. The family members will be identified
by the proband or proband's parent when the initial pedigree is taken. Subjects considered
by the investigators to be appropriate for linkage studies will be invited to participate by
the local genetics provider or by the investigators, who will then connect these members to
their own local providers for enrollment.
In our studies of inherited urologic malignant disorders, there may be individuals from
renal cancer families who do not undergo clinical evaluation for the presence of an
inherited urologic malignant disorder at the National Institutes of Health because of their
health problems, geographical location, or personal preference. Even though these
individuals do not undergo a clinical evaluation of their suspected inherited urologic
malignant disorder at the National Institutes of Health, they may have rare diseases that
are extremely important to study. Therefore, we intend to collect blood samples for genetic
studies from these individuals to facilitate linkage analysis and disease gene
identification. Samples will be collected either by the individual's physician and sent to
NIH, or will be collected by NIH physicians at either the individual's off-site location or
at the NIH.
Investigation of the causes of genetic defects relating to hereditary urologic malignancies
will be undertaken. These rare disorders result from inherited or newly arising mutations in
genes involved in the development and function of different organ systems. As specific
disease syndromes are recognized and the responsible genes identified, mutations in
individual families can be identified. Correlation of mutation sites with clinical
information will help determine how specific gene segments encode important functional
protein domains.
Families with urologic malignant disorders of known or suspected genetic basis will be
enrolled. Genetic linkage studies will include all available family members, while gene
sequence analysis will be performed on affected individuals. Unaffected family members or
unrelated normal individuals will serve as controls. The family members will be identified
by the proband or proband's parent when the initial pedigree is taken. Subjects considered
by the investigators to be appropriate for linkage studies will be invited to participate by
the local genetics provider or by the investigators, who will then connect these members to
their own local providers for enrollment.
In our studies of inherited urologic malignant disorders, there may be individuals from
renal cancer families who do not undergo clinical evaluation for the presence of an
inherited urologic malignant disorder at the National Institutes of Health because of their
health problems, geographical location, or personal preference. Even though these
individuals do not undergo a clinical evaluation of their suspected inherited urologic
malignant disorder at the National Institutes of Health, they may have rare diseases that
are extremely important to study. Therefore, we intend to collect blood samples for genetic
studies from these individuals to facilitate linkage analysis and disease gene
identification. Samples will be collected either by the individual's physician and sent to
NIH, or will be collected by NIH physicians at either the individual's off-site location or
at the NIH.
;
N/A
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00151034 -
Trastuzumab (Herceptin), Paclitaxel, Carboplatin and Gemcitabine in Advanced Urothelial Cancer
|
Phase 2 | |
Completed |
NCT04933604 -
LPN in Patients With High-complex Renal Tumors
|
||
Completed |
NCT03219333 -
A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
|
Phase 2 | |
Completed |
NCT04052113 -
Real World Evidence of PD-L1, TMB Prevalence and Efficacy of 1st Line Chemotherapy in These High or Low Population for Stage IV Urothelial Cancer
|
||
Terminated |
NCT02543645 -
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
|
Phase 1 | |
Completed |
NCT01454089 -
A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03288545 -
A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05025930 -
Evaluate the Safety and Effectiveness of the Endoscopic Surgical Instrument Control System (SP1000).
|
N/A | |
Not yet recruiting |
NCT05135520 -
Transvaginal Versus Transabdominal Extraction of Laparoscopically-excised Kidney Specimen
|
N/A | |
Withdrawn |
NCT04630483 -
Platelet-lymphocyte and Neutrophil-lymphocyte Ratio in Patients Undergoing Cancer Surgery
|
||
Terminated |
NCT02386111 -
A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma
|
Phase 1 | |
Completed |
NCT03081858 -
Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT04644432 -
Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma
|
Phase 2 | |
Recruiting |
NCT05308771 -
To Investigate the Use of a New Syringe "Visual Pressure Control (VPC)" for Epidural Anesthesia in Children Surgery
|
N/A | |
Terminated |
NCT00226954 -
Zoledronic Acid With Intermittent Hormonal Therapy in Patients With Prostate Cancer
|
Phase 2 | |
Completed |
NCT05113134 -
Transvaginal Versus Transabdominal Extraction of Laparoscopically-excised Specimen
|
N/A | |
Completed |
NCT04213157 -
Laparoscopic Partial Nephrectomy for cT1 Tumors
|
||
Completed |
NCT02780687 -
Afatinib Monotherapy in Patients With ERBB-deregulated Metastatic Urothelial Tract Carcinoma After Failure of Platinum Based Chemotherapy
|
Phase 2 | |
Recruiting |
NCT04922047 -
Safety and Efficacy Study of Tislelizumab in Combination With BCG in HR-NMIBC Patients (TACBIN-01)
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06353906 -
Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer
|
Phase 2 |